P. Lara

D. Gandara, R. Salgia, M. Edelman, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Platinum‐free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma

M. Edelman, N. Dawson, P. Lara, 2004, Cancer.

Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour.

R. Gandour-Edwards, M. Dall’Era, P. Lara, 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Asian American Network for Cancer Awareness, Research, and Training (AANCART): Fifth Asian American Cancer Control Academy

L. Beckett, D. Paterniti, Nora Horan, 2005 .

Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer.

D. Gandara, P. Mack, N. Goodwin, 2014, The Journal of thoracic and cardiovascular surgery.

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.

M. Gleave, C. Maher, L. True, 2019, European urology.

A Population-Based Study of Incidence and Survival of 1588 Thymic Malignancies: Results From the California Cancer Registry.

J. Riess, R. Cress, P. Lara, 2019, Clinical lung cancer.

Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879

S. Groshen, D. Gandara, H. Lenz, 2021, Investigational New Drugs.

Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.

S. Cherry, L. Nardo, J. Riess, 2020, Clinical lung cancer.

Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.

L. Fehrenbacher, P. Lara, H. West, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

Keunchil Park, D. Gandara, J. Infante, 2013 .

Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)

J. Crowley, D. Gandara, W. Franklin, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124

N. Saijo, D. Gandara, H. Lenz, 2007 .

2007 Highlights from: the 12th World Conference on Lung Cancer Seoul, South Korea; September 2-6, 2007

R. Herbst, D. Gandara, C. Langer, 2007 .

PD-075 Consolidation docetaxel (D) following concurrentchemoradiotherapy (chemoRT) in stage IIIB non-small cell lung cancer (NSCLC): Updated five-year survival results from Southwest Oncology Group trial S9504

D. Gandara, L. Gaspar, J. Crowley, 2005 .

Treatment of extensive small cell lung cancer.

D. Gandara, A. Davies, P. Lara, 2004, Hematology/oncology clinics of North America.

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

P. Lara, S. Christensen, T. Semrad, 2013, Anti-cancer drugs.

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.

N. Saijo, D. Gandara, K. Chansky, 2010, Cancer.

Phase I Trial of Gemcitabine and Paclitaxel in Advanced Solid Tumors

D. Gandara, M. Edelman, P. Lara, 2003, Cancer investigation.

Medical oncology: Chemoradiotherapy for NSCLC—does a 'standard' exist?

P. Lara, A. Chen, 2011, Nature Reviews Clinical Oncology.

Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials

J. Crowley, N. Saijo, Y. Nishiwaki, 2004 .

Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer

D. Gandara, P. Mack, P. Lara, 2011, Current opinion in oncology.

Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.

D. Gandara, P. Mack, P. Lara, 2008, Clinical Lung Cancer.

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer

J. Riess, D. Gandara, P. Lara, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC)

J. Crowley, J. Jett, H. Lenz, 2008 .

Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology

R. Herbst, D. Gandara, P. Lara, 2009 .

Highlights from: The 2009 Annual Meeting of the American Society of Clinical Oncology Orlando, FL May 29-June 2, 2009

R. Herbst, D. Gandara, P. Lara, 2009 .

Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results.

S. Ramalingam, P. Lara, 2008, Clinical lung cancer.

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.

R. Bold, M. Schlieman, S. Virudachalam, 2005, Lung cancer.

Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma

D. Gandara, M. Edelman, P. Gumerlock, 2003, Cancer Chemotherapy and Pharmacology.

Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach.

D. Gandara, P. Gumerlock, P. Mack, 2001, Lung cancer.

Intermittent erlotinib in combination with docetaxel (DOC): Phase I schedules designed to achieve pharmacodynamic separation

D. Gandara, P. Gumerlock, P. Mack, 2005 .

Local Radiation for Extensive Stage Small Cell Lung Cancer: A Step Forward or Running in Place?

M. Daly, P. Lara, 2016, Clinical lung cancer.

Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.

J. Doroshow, V. Israel, D. Gandara, 2004, Clinical lung cancer.

Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the ‘common arm’ approach

D. Gandara, P. Mack, P. Lara, 2012, Expert review of anticancer therapy.

Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 30-June 3, 2008

R. Herbst, D. Gandara, P. Lara, 2008 .

Incorporating Bortezomib into the Treatment of Lung Cancer

D. Gandara, P. Mack, A. Davies, 2007, Clinical Cancer Research.

Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer

L. Beckett, D. Gandara, A. Davies, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial

H. Wakelee, T. Lynch, V. Miller, 2008 .

Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.

D. Gandara, P. Gumerlock, P. Mack, 2007, Clinical lung cancer.

Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study

L. Beckett, D. Gandara, A. Davies, 2007, Investigational New Drugs.

Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial

J. Doroshow, D. Gandara, H. Lenz, 2005, Anti-cancer drugs.

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.

J. Doroshow, D. Gandara, P. Gumerlock, 2004, Clinical lung cancer.

Current applications for prostate-specific antigen doubling time.

R. deVere White, P. Lara, C. Evans, 2008, European urology.

Kidney Cancer Incidence in California: End of the Trend?

K. Kizer, P. Lara, C. Morris, 2017, Kidney cancer.

Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer.

J. Rigas, P. Lara, 2005, Lung cancer.

A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).

P. Jänne, H. Wakelee, J. Engelman, 2010 .

Trametinib plus 4‐Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD‐1 and PD‐L1 in Malignant Pleural Mesothelioma

T. Nakano, D. Gandara, M. Sonobe, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An Evaluation of Barriers to Accrual in the Era of Legislation Requiring Insurance Coverage of Cancer Clinical Trial Costs in California

L. Beckett, D. Gandara, H. Chew, 2004, Cancer journal.

The hazards of randomized phase II trials.

P. Lara, M. Redman, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

L. Beckett, R. Gandour-Edwards, J. LaSalle, 2002, Cancer.

A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).

David C. Smith, C. Tangen, E. Crawford, 2009, The Journal of urology.

Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.

K. Turteltaub, P. Lara, P. Henderson, 2010, Chemical research in toxicology.

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

F. Meyers, G. Denardo, S. Denardo, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

HER‐2/neu is overexpressed infrequently in patients with prostate carcinoma

J. Doroshow, D. Gandara, P. Gumerlock, 2002, Cancer.

Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy

C. Tepper, D. Gandara, P. Mack, 2011, Cancer Chemotherapy and Pharmacology.

Cytokines in the Management of Advanced Renal Cell Cancer

P. Lara, A. Pai, 2012 .

MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates

M. Socinski, R. Herbst, F. Hirsch, 2017 .

Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.

S. Dakhil, C. Ryan, E. Crawford, 2008, Clinical genitourinary cancer.

A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).

L. Schwartz, R. Herbst, F. Hirsch, 2019, Journal of Clinical Oncology.

Progress in small-cell lung cancer: the lowest common denominator.

D. Gandara, P. Lara, R. Natale, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

S. Patel, P. LoRusso, S. Piha-Paul, 2019, Clinical Cancer Research.

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

D. Smith, E. Small, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined modality radioimmunotherapy (RIT) in metastatic prostate (PC) and breast cancer (BC) using paclitaxel (PT) and a MUC-1 monoclonal antibody, m170, linked to yttrium-90 (Y-90): A phase I trial.

G. Denardo, S. Denardo, P. Lara, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non e small-cell Lung Cancer

D. Gandara, R. Perez-soler, Mimi Kim, 2017 .

A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients (NCI 10327): Rationale and Study Design

Ian R. Lanza, S. Cherry, L. Nardo, 2021 .

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity

Joel A. Yates, Christopher K. Wong, M. Gleave, 2022, Nature Communications.

Combination Treatment of Prostate Cancer Cell Lines with Bioactive Soy Isoflavones and Perifosine Causes Increased Growth Arrest and/or Apoptosis

P. Ghosh, R. Vinall, P. Lara, 2007, Clinical Cancer Research.

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).

K. Owzar, T. Ho, T. Choueiri, 2021, The oncologist.

Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases.

D. Quinn, P. Lara, 2015, The New England journal of medicine.

Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications

P. Lara, C. Evans, C. Pan, 2007, World Journal of Urology.

Gemcitabine/carboplatin combination regimens: importance of dose schedule.

D. Gandara, M. Edelman, P. Lara, 2000, Oncology.

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer

M. Fishman, T. Dorff, W. Stadler, 2017, Cancer.

Malignant thymoma: current status and future directions.

P. Lara, 2000, Cancer treatment reviews.

Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry

R. Cress, M. Dall’Era, P. Lara, 2014, World Journal of Urology.

Predictive molecular markers: has the time come for routine use in lung cancer?

D. Gandara, K. Danenberg, P. Gumerlock, 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer".

D. Gandara, P. Lara, M. Redman, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412.

C. Ryan, H. Drabkin, T. Beer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA).

C. Tangen, E. Small, D. Petrylak, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.

C. Tangen, E. Crawford, P. Lara, 2009, The Journal of urology.

SWOG S0354: A phase II trial of CNTO328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pretreated patients (pts) with castration- resistant prostate cancer (CRPC).

J. Pinski, I. Thompson, T. Dorff, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Premedication Strategy for Weekly Paclitaxel

D. Gandara, P. Lara, D. Lau, 2002, Cancer investigation.

The Src Inhibitor AZD0530 Blocks Invasion and May Act as a Radiosensitizer in Lung Cancer Cells

C. Tepper, D. Gandara, H. Kung, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)

S. Balcerzak, W. Samlowski, E. Crawford, 1998, Investigational New Drugs.

Thymoma-associated multiorgan autoimmunity: a graft-versus-host-like disease.

N. Mitsiades, P. Lara, M. Fung, 2007, Journal of the American Academy of Dermatology.

communications to the editorSalvage Chemotherapy for Recurrent Invasive Thymoma

P. Lara, P. Bonomi, L. Faber, 1997 .

Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide.

P. Lara, P. Bonomi, L. Faber, 1996, Chest.

The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial

J. Doroshow, D. Gandara, P. Gumerlock, 2005, Clinical Cancer Research.

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial

E. Perez, J. Doroshow, V. Israel, 2001, Cancer Chemotherapy and Pharmacology.

Phase I and correlative science trial of UCN-01 plus cisplatin (CDDP) in advanced solid tumors: A California Cancer Consortium study.

J. Doroshow, D. Gandara, P. Gumerlock, 2004, Journal of Clinical Oncology.

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

I. Thompson, C. Tangen, M. Carducci, 2018, Cancer treatment and research communications.

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

C. Tangen, E. Crawford, W. Sakr, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.

R. Herbst, J. Bradley, K. Kelly, 2017 .

Eribulin in advanced urothelial cancer (AUC) patients (pts): A California Cancer Consortium trial—NCI/CTEP 7435.

S. Groshen, T. Dorff, W. Stadler, 2015 .

Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)--Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial.

S. Groshen, D. Gandara, T. Dorff, 2010 .

Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC).

D. Gandara, P. Mack, P. Lara, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward

J. Manola, S. Signoretti, B. Shuch, 2017, Kidney cancer.

ATR Inhibition in Advanced Urothelial Carcinoma.

Mei-Juan Tu, P. Lara, M. Parikh, 2022, Clinical genitourinary cancer.

Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma

J. Blay, P. Hammerman, A. Italiano, 2016 .

The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced SolidTumors : ACalifornia Cancer Consortium Phase I Pharmacokinetic andMolecular Correlative Trial

J. Doroshow, D. Gandara, P. Gumerlock, 2005 .

Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504)

D. Gandara, L. Gaspar, K. Chansky, 2005 .

A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome.

R. Cress, M. Dall’Era, P. Lara, 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Pathologic stage IIIb non-small cell lung cancer (NSCLC): Prolonged survival with consoloidation Docetaxel following concurrent chemoradiotherapy (SWOG 9504)

R. Livingston, D. Gandara, J. Crowley, 2000 .

Evolution of combined modality therapy for stage III non-small-cell lung cancer.

D. Gandara, M. Edelman, P. Lara, 2000, Oncology.

Effective treatment strategies for stage IIIA NSCLC

P. Lara, A. Metzger, 2006 .

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer

N. Agarwal, M. Dall’Era, P. Lara, 2021, Scientific reports.

Prospective E valuation o f C ancer C linical T rial A ccrual Patterns: I dentifying P otential B arriers t o E nrollment

D. Gandara, P. Lara, F. Meyers, 2001 .

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib

H. Wakelee, T. Lynch, V. Miller, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342.

J. Crowley, R. Herbst, K. Kelly, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

S. Signoretti, B. Leibovich, T. Choueiri, 2019, Future oncology.

O-89 S0003: Paclitaxel/carboplatin (PC) versus PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III southwest oncology group (SWOG) trial

J. Crowley, D. Gandara, P. Lara, 2003 .

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

F. Saad, H. Scher, D. George, 2019, Annals of Oncology.

Aurora kinase inhibitors: a new class of targeted drugs in cancer.

D. Gandara, P. Mack, A. Davies, 2006, Clinical lung cancer.

Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.

Donna L Berry, E. Crawford, D. Ankerst, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

H. Scher, D. George, E. Yu, 2019, Journal of Clinical Oncology.

Dehydroepiandrosterone (DHEA) in metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Dream Team (WCDT).

R. Baertsch, M. Gleave, E. Small, 2016 .

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

S. Steinberg, H. Parnes, J. Trepel, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC).

R. Figlin, J. Rosenberg, H. Drabkin, 2010 .

A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non–Small Cell Lung Cancer

Stephen C. Grubb, Michael W. Lloyd, C. Bult, 2022, bioRxiv.

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

S. Steinberg, Yipeng Wang, J. Trepel, 2020, Clinical Cancer Research.

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.

P. Paik, E. Felip, D. Morgensztern, 2019, Lung cancer.

Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer

K. Lam, Juntao Luo, P. Lara, 2012, International journal of nanomedicine.

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

L. Beckett, J. Riess, D. Gandara, 2013, Investigational New Drugs.

Neovaginal malignant melanoma following surgery and radiation for vulvar squamous cell carcinoma.

P. Lara, B. Leigh, E. Hearn, 1997, Gynecologic oncology.

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

J. Pinski, I. Thompson, T. Dorff, 2010, Clinical Cancer Research.

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

L. Garraway, R. Figlin, T. Choueiri, 2014, Investigational New Drugs.

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

R. Motzer, J. Bacik, M. Mazumdar, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.

J. Crowley, D. Gandara, W. Franklin, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

P. Jänne, H. Wakelee, J. Engelman, 2017, Cancer Chemotherapy and Pharmacology.

Prostate cancer: Predicting response to androgen receptor signalling inhibition

P. Lara, C. Evans, 2014, Nature Reviews Urology.

Aurora Kinases as Anticancer Drug Targets

Oliver Gautschi, D. Gandara, J. Heighway, 2008, Clinical Cancer Research.

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity

J. Gregg, N. Agarwal, E. Sokol, 2020, JCO precision oncology.

Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

P. Hammerman, F. Hirsch, D. Gandara, 2015, Clinical Cancer Research.

Metabolic reprogramming in clear cell renal cell carcinoma

R. Weiss, Omran Abu Aboud, P. Lara, 2017, Nature Reviews Nephrology.

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

K. Do, E. Jonasch, K. Shaw, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

J. McPherson, P. Stephens, J. Riess, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular biology of prostate carcinogenesis.

P. Gumerlock, P. Lara, F. Meyers, 1999, Critical reviews in oncology/hematology.

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

J. Crowley, J. Jett, D. Gandara, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.

S. Groshen, J. Pinski, D. Gandara, 2009, Clinical genitourinary cancer.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors

J. Gregg, N. Agarwal, E. Sokol, 2019, JCO precision oncology.

Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors

K. Kelly, D. Gandara, J. Bomalaski, 2015, Clinical Cancer Research.

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

L. Beckett, J. Riess, K. Kelly, 2021, JCO precision oncology.

D. Gandara, K. Danenberg, P. Mack, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antimicrotubule-Platinum Therapy in NSCLS by Histologic Subtypes 628-Introduction

F. Hirsch, A. Wozniak, D. Gandara, 2022 .

Angiogenesis-targeted therapies in prostate cancer.

D. Quinn, P. Lara, P. Twardowski, 2004, Clinical prostate cancer.

Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study.

J. Doroshow, D. Gandara, P. Gumerlock, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap.

D. Gandara, P. Mack, P. Lara, 2015, Journal of Clinical Oncology.

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

C. Bult, E. Liu, J. Riess, 2015, Clinical lung cancer.

Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma.

T. Choueiri, P. Ravi, P. Lara, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.

D. Gandara, H. Lenz, A. Hölscher, 2014, Lung cancer.

Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.

P. Lara, M. Parikh, 2018, Annual review of medicine.

Phase I study of INC280 plus erlotinib in patients with MET expressing adenocarcinoma of the lung.

L. Beckett, J. Riess, K. Kelly, 2015 .

Progress in Personalizing Chemotherapy for Bladder Cancer

P. Lara, C. Pan, James S. Chang, 2012, Advances in urology.

Defining an individualized treatment strategy for metastatic renal cancer.

P. Lara, C. Evans, B. Hu, 2012, The Urologic clinics of North America.

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

S. Steinberg, H. Parnes, M. Merino, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500.

I. Thompson, C. Tangen, B. Shuch, 2017 .

Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

W. Samlowski, R. Nagle, P. Mack, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Renal cell carcinoma: current status and future directions.

P. Lara, C. Martel, 2003, Critical reviews in oncology/hematology.

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.

C. Tangen, C. Ryan, P. Mack, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer

L. Beckett, D. Gandara, P. Mack, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Renal cell carcinoma: current status and emerging therapies.

P. Lara, C. Evans, E. Nelson, 2007, Cancer treatment reviews.

Bortezomib-based combinations in the treatment of non-small-cell lung cancer.

Richard J Bold, D. Gandara, R. Bold, 2005, Clinical lung cancer.

Common arm comparative outcomes analysis of phase III trials of cisplatin + irinotecan vs. cisplatin + etoposide in extensive stage small cell lung cancer: Final patient-level results from JCOG 9511 and SWOG 0124

N. Saijo, D. Gandara, K. Chansky, 2011 .

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer 1

N. Saijo, D. Gandara, K. Chansky, 2010 .

Cooperative group research endeavors in small-cell lung cancer: current and future directions.

H. Choy, N. Saijo, D. Gandara, 2009, Clinical lung cancer.

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

C. Tangen, E. Crawford, D. Ankerst, 2006, Journal of the National Cancer Institute.

Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

R. Baertsch, M. Gleave, L. True, 2015 .

Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.

G. Scagliotti, J. von Pawel, D. Heo, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to E.S. Wang et al

P. Lara, M. McKeage, 2012 .

Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.

J. Crowley, D. Gandara, P. Lara, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111)

W. Sakr, D. Petrylak, E. Crawford, 2004 .

Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111).

W. Sakr, D. Petrylak, E. Crawford, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

M. Socinski, M. Edelman, J. Vansteenkiste, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast Prostate

M. Gleave, L. True, F. Feng, 2020 .

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

I. Thompson, C. Tangen, N. Agarwal, 2013, The Lancet. Oncology.

Treatment options in androgen-independent prostate cancer.

P. Lara, F. Meyers, P. N. Lara, 1999, Cancer investigation.

Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial

D. Smith, D. Petrylak, D. Trump, 2005 .

A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer

P. Kantoff, W. Oh, J. Doroshow, 2004, Clinical Cancer Research.

Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916.

D. Pauler, C. Tangen, E. Small, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

I. Thompson, C. Tangen, L. Fink, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Casting a wide net: HSP90 inhibition to circumvent resistance to TKIs in EGFR-mutated and ALK-rearranged NSCLC

J. Riess, P. Lara, 2015 .

SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.

J. Doroshow, D. Gandara, H. Lenz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

J. Pignon, P. Laurent-Puig, C. Punt, 2014, The Pharmacogenomics Journal.

Gemcitabine in combination with new platinum compounds: an update.

D. Gandara, M. Edelman, P. Lara, 2001, Oncology.

Preclinical Evaluation of MET Inhibitor INC‐280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small‐Cell Lung Cancer

K. Kelly, D. Gandara, P. Mack, 2017, Clinical lung cancer.

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer

D. Gandara, K. Danenberg, P. Danenberg, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

2007 Highlights from: the 24th Annual Meeting of the American Association for Cancer Research Los Angeles, CA; April 14–18, 2007

P. Lara, A. Ranganathan, S. Muneer, 2007 .

Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma

D. Gandara, M. Edelman, P. Lara, 2001, Cancer.

Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.

J. Doroshow, V. Israel, D. Gandara, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New and emerging developments in extensive-stage small cell lung cancer therapeutics

J. Riess, P. Lara, M. Parikh, 2016, Current opinion in oncology.

Left behind? Drug discovery in extensive-stage small-cell lung cancer.

J. Riess, P. Lara, 2014, Clinical lung cancer.

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

J. Crowley, C. Coltman, H. McLeod, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.

L. Schwartz, R. Herbst, F. Hirsch, 2021, Clinical Lung Cancer.

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).

S. Groshen, T. Dorff, L. Doyle, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048

S. Groshen, D. Gandara, P. Mack, 2018, Kidney cancer.

NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma

J. Kirkwood, A. Chen, H. Tawbi, 2018, Cancer.

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small‐cell Lung Cancer

L. Beckett, D. Gandara, R. Perez-soler, 2017, Clinical lung cancer.

Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.

K. Kelly, D. Gandara, J. Moon, 2016, Clinical lung cancer.

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Mary W Redman, Karen Kelly, J. Crowley, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

J. Riess, K. Kelly, D. Gandara, 2014, Clinical Lung Cancer.

Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer

K. Kelly, P. Mack, M. Daly, 2013 .

Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.

J. Crowley, D. Moore, D. Gandara, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

Edward J. Kim, L. Beckett, A. Barzi, 2015, International Journal of Clinical Oncology.

Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group

W. Linehan, G. Carvalhal, P. Spiess, 2021, JCO global oncology.

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.

David C. Smith, R. Dunn, D. Petrylak, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

M. Gleave, E. Small, J. Youngren, 2014 .

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial

Y. Tai, I. Thompson, C. Tangen, 2015, International journal of cancer.

Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients

L. Beckett, P. Lara, C. Pan, 2015, Prostate Cancer and Prostatic Disease.

Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.

D. Gandara, P. Gumerlock, P. Mack, 2006, Clinical lung cancer.

Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial

J. Doroshow, D. Gandara, H. Lenz, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

S. Hancock, R. Motzer, E. Jonasch, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier

D. Gandara, P. Mack, P. Lara, 2009, Current opinion in oncology.

2006 Highlights From: The European Society for Medical Oncology Congress Istanbul, Turkey; Sept. 29-Oct. 3, 2006 International Association for the Study of Lung Cancer Early Invasive Lung Cancer Workshop Turin, Italy; Sept. 25–26, 2006

A. Adjei, P. Lara, A. Ranganathan, 2006 .

The 2010 Meeting of the American Society of Clinical Oncology

D. Gandara, C. Langer, P. Lara, 2010 .

Highlights from: The 13th world conference on lung cancer

R. Herbst, D. Gandara, P. Lara, 2009 .

Results of a Phase II Placebo‐controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small‐cell Lung Carcinoma

H. Kluger, D. Ramies, B. Hellerstedt, 2019, Clinical lung cancer.

Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.

J. Doroshow, D. Gandara, H. Lenz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy—California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial

S. Groshen, D. Gandara, D. Quinn, 2008 .

Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience

D. Gandara, P. Lara, T. Semrad, 2011, Therapeutic advances in medical oncology.

A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

J. Doroshow, D. Gandara, H. Lenz, 2006, Clinical Cancer Research.

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

E. V. Van Allen, S. Signoretti, T. Choueiri, 2019 .

PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

S. Signoretti, B. Leibovich, T. Choueiri, 2019, Journal of Clinical Oncology.

Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials.

Moon S. Chen, L. Beckett, D. Gandara, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant Chemotherapy: The New Standard

P. Lara, K. Chee, 2009 .

Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.

D. Gandara, R. Bold, P. Gumerlock, 2005, Clinical lung cancer.

A Phase II Study of Gemcitabine and Capecitabine in Patients With Advanced Renal Cell Cancer: Southwest Oncology Group Study S0312

R. Gandour-Edwards, P. Mack, P. Lara, 2009, American journal of clinical oncology.

Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.

P. Lara, Monica Brown, C. Pan, 2012, Clinical genitourinary cancer.

Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer.

C. Tepper, D. Gandara, H. Kung, 2008, Cancer research.

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

Tianhong Li, Sanjiv S. Agarwala, Scott D. Christensen, 2010, Investigational New Drugs.

Integration of Novel Therapeutics into Combined Modality Therapy of Locally Advanced Non–Small Cell Lung Cancer

D. Gandara, Srinivasan Vijayakumar, P. Gumerlock, 2005, Clinical Cancer Research.

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

D. Gandara, E. Heath, W. Stadler, 2010, Urology.

A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316).

C. Gotay, C. Moinpour, A. Wozniak, 2012, The oncologist.

SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC).

I. Thompson, C. Tangen, N. Agarwal, 2012 .

O-3 Randomized phase II study of the novel tubulin targetin agent, BMS-247550 (Epothilone B analogue) in the treatment of non-small cell lung cancer (NSCLC) in patients (pts) who have failed first line platinum containing therapy

M. Edelman, L. Paz-Ares, J. Vansteenkiste, 2003 .

TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies.

J. McPherson, P. Stephens, V. Miller, 2017, JCO Precision Oncology.

Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited.

D. Gandara, D. Nguyen, P. Lara, 2008, Archives of internal medicine.

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

D. Gandara, K. Chansky, J. Crowley, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Proteasome Inhibitor Bortezomib in Combination with Gemcitabine and Carboplatin in Advanced Non-small Cell Lung Cancer: A California Cancer Consortium Phase I Study

D. Gandara, H. Lenz, R. Bold, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

晚期非小细胞肺癌治疗策略的演变：从2009放眼2012

R. Herbst, D. Gandara, P. Mack, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012.

R. Herbst, D. Gandara, P. Mack, 2009, Clinical lung cancer.

Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation

L. Beckett, D. Gandara, A. Davies, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.

G. Scagliotti, D. Gandara, P. Mack, 2009, Clinical lung cancer.

Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.

F. Hirsch, K. Kelly, A. Wozniak, 2013, Clinical lung cancer.

Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

T. Ho, T. Choueiri, N. Agarwal, 2019, Annals of Oncology.

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

E. Heath, P. Mack, A. Hussain, 2019, The oncologist.

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration‐Resistant Prostate Cancer Treated on SWOG Study S0421

G. Pond, I. Thompson, C. Tangen, 2017, Clinical genitourinary cancer.

Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).

J. Pinski, S. Ingles, I. Thompson, 2016 .

Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.

D. Gandara, P. Lara, R. Natale, 2006, Clinical lung cancer.

Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Joshua M. Stuart, M. Gleave, T. Goldstein, 2016 .

The AKT inhibitor perifosine in biochemically recurrent, hormone-sensitive prostate cancer (HSPC): A phase II California Cancer Consortium trial

D. Gandara, D. Quinn, G. Chatta, 2005 .

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

I. Thompson, C. Tangen, A. Goldkorn, 2014, Journal of the National Cancer Institute.

Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum‐Refractory Urothelial Cancer: Results From a Phase I Study

L. Beckett, P. Lara, Yueju Li, 2018, Clinical genitourinary cancer.

Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)

M. Meng, I. Thompson, C. Tangen, 2019, Kidney Cancer.

The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy

A. Barzi, I. Gill, M. Aron, 2022, Cancers.

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

Gurkamal Chatta, Christopher P Evans, D. Gandara, 2009, Anti-cancer drugs.

Racial Disparities on the Use of Invasive and Noninvasive Staging in Patients with Non-small Cell Lung Cancer

K. Yoneda, D. Gandara, D. Nguyen, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Racial disparities on the use of invasive and noninvasive staging in patients (pts) with non-small cell lung cancer (NSCLC).

K. Yoneda, D. Gandara, D. Nguyen, 2010 .

Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium

D. Gandara, D. Quinn, P. Frankel, 2007, Journal of Cancer Research and Clinical Oncology.

Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.

D. Gandara, P. Gumerlock, P. Mack, 2003, Lung cancer.

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib

M. Socinski, K. Kelly, D. Gandara, 2015, Clinical Cancer Research.

Phase 0 microdose trial to identify chemoresistance in lung and bladder cancer.

D. Gandara, K. Turteltaub, P. Mack, 2010 .

The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.

J. Pinski, D. Gandara, D. Quinn, 2007, Clinical genitourinary cancer.

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

I. Thompson, C. Tangen, C. Moinpour, 2018, Journal of Patient-Reported Outcomes.

I. Thompson, C. Tangen, C. Moinpour, 2018 .

Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.

E. Messing, C. Tangen, B. Shuch, 2019, European urology focus.

Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.

D. Gandara, F. Shepherd, S. Ramalingam, 2011, Clinical lung cancer.

Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach.

K. Lam, C. Evans, P. Lara, 2012, Urologic oncology.

Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.

F. Hirsch, D. Gandara, P. Mack, 2007, Clinical lung cancer.

Nephrectomy Status in the Context of Cabozantinib Treatment

P. Lara, M. Parikh, Naseem S Esteghamat, 2020 .

Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

R. Herbst, J. Bradley, K. Kelly, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

G. Shapiro, E. Swisher, G. Bubley, 2021 .

Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.

S. Groshen, C. Paweletz, P. Jänne, 2019, Journal of Clinical Oncology.

KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536.

R. Herbst, F. Hirsch, D. Gandara, 2009, Journal of Clinical Oncology.

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncology Group Trials

K. Kelly, D. Gandara, J. Moon, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Relevance of platinum sensitivity status in relapsed/refractory extensive stage small cell lung cancer (ES-SCLC) in the modern era: A patient level analysis of SWOG trials

K. Kelly, D. Gandara, J. Moon, 2015 .

Phase II study of aflibercept (VEGF-Trap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: A California Cancer Consortium trial.

D. Gandara, E. Heath, W. Stadler, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular-disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC).

G. Scagliotti, J. von Pawel, D. Heo, 2011, Journal of Clinical Oncology.

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway – Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

R. Herbst, J. Bradley, K. Kelly, 2019 .

Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase II clinical trial.

L. Beckett, P. Ghosh, P. Lara, 2010, Journal of Clinical Oncology.

Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.

David C. Smith, E. Schmidt, V. Borges, 2017 .

Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.

F. Saad, H. Scher, D. George, 2020 .

The proteasome inhibitor PS-341 (bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): A SWOG (0327) phase II trial

D. Gandara, K. Chansky, R. Bold, 2005 .

Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).

S. Steinberg, H. Parnes, M. Bagheri, 2018 .

A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).

M. Dall’Era, C. Evans, P. Lara, 2018 .

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.

J. Riess, K. Kelly, D. Gandara, 2017, Clinical lung cancer.

Reconciling the Role of Vascular Endothelial Growth Factor-Targeted Therapies in Adjuvant Renal Cell Carcinoma Treatment

C. Ryan, P. Lara, W. Kim, 2018, Kidney Cancer.

Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Abhijit A. Patel, E. Swisher, P. LoRusso, 2020 .

Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: Implications for clinical trial design.

J. Crowley, K. Kelly, D. Gandara, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.

L. Beckett, K. Kelly, D. Gandara, 2012, Clinical lung cancer.

OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D

M. Socinski, J. Engelman, R. Herbst, 2017 .

Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

D. Gandara, P. Mack, A. Davies, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A sequential treatment approach to muscle-invasive urothelial cancer: A phase II Southwest Oncology Group Trial (S0219) of neoadjuvant paclitaxel, carboplatin, and gemcitabine (PCG)

David C. Smith, C. Tangen, E. Crawford, 2008 .

Enzalutamide and metformin combination therapy to overcome autophagy resistance in castration resistant prostate cancer (CRPC): Current results from a phase I study.

C. Evans, P. Lara, C. Pan, 2018 .

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

I. Thompson, C. Tangen, N. Agarwal, 2017, Kidney cancer.

Activity of the Src-kinase inhibitor AZD0530 in androgen-independent prostate cancer (AIPC): Pre-clinical rationale for a phase II trial.

H. Kung, J. Yang, P. Lara, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Untargeted Use of Targeted Therapy

D. Gandara, P. Gumerlock, P. Mack, 2008 .

Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.

D. Gandara, R. Bold, P. Gumerlock, 2004, Seminars in oncology.

A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).

S. Signoretti, T. Choueiri, M. Michaelson, 2017 .

Overcoming barriers to cancer clinical trial accrual

Moon S. Chen, L. Beckett, D. Gandara, 2008, Cancer.

Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonism

L. Beckett, D. Gandara, P. Mack, 2007 .

Randomized phase II CTEP study of MK2206 versus everolimus in VEGF inhibitor refractory renal cell carcinoma patients.

K. Do, E. Jonasch, P. Corn, 2013 .

The Promise and Disappointment of Neoadjuvant Chemotherapy and Transurethral Resection for Muscle Invasive Bladder Cancer: Updated Results and Long‐Term Followup

R. deVere White, M. Dall’Era, P. Lara, 2017, Urology practice.

Title The Promise and Disappointment of Neoadjuvant Chemotherapy and Transurethral Resection for Muscle Invasive Bladder Cancer : Updated Results and Long-Term Followup Permalink

P. Lara, R. D. White, T. Chandrasekar, 2022 .

Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291.

J. Doroshow, D. Gandara, E. Vokes, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

S. Signoretti, B. Leibovich, T. Choueiri, 2019, Journal of Clinical Oncology.

Adjuvant Therapy in Completely Resected Malignant Thymoma

P. Lara, 2003, Cancer investigation.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay

F. Hirsch, D. Gandara, J. Moon, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognotic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC).

Y. Tai, I. Thompson, C. Tangen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials.

J. Crowley, N. Saijo, Y. Nishiwaki, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In Search of an Oncogene Driver for Squamous Lung Cancer.

J. Riess, D. Gandara, P. Lara, 2018, JAMA oncology.

Humanized mice (humice) carrying patient-derived xenograft (PDX) as a platform to develop immunotherapy in bladder cancer (BCa).

K. Palucka, J. Keck, S. Airhart, 2017 .

The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Joshua M. Stuart, M. Gleave, E. Small, 2014 .

Addressing rural disparities in cancer care via telehealth.

E. M. Kaime, R. Bold, P. Lara, 2020 .

Preclinical rationale for combination targeted therapy in advanced clear cell renal cell carcinoma (RCC): Abrogation of rapamycin-mediated induction of AKT phosphorylation by perifosine

D. Gandara, P. Mack, P. Lara, 2008 .

SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC).

I. Thompson, C. Tangen, N. Agarwal, 2015 .

A multi-institution phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer

D. Gandara, L. Fehrenbacher, A. Davies, 2005 .

Asian Americans and cancer clinical trials

Moon S. Chen, L. Beckett, D. Paterniti, 2005, Cancer.

Papillary renal cell carcinoma: current progress and future directions.

P. Mack, P. Lara, P. Twardowski, 2014, Clinical genitourinary cancer.

The JAX patient-derived xenograft program: A unique resource to advance genome-guided cancer medicine and therapeutic agent testing.

Jeffrey H. Chuang, C. Bult, J. George, 2014 .

2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006

R. Herbst, F. Hirsch, H. Pass, 2007 .

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

J. Pinski, S. Ingles, I. Thompson, 2021, Clinical Cancer Research.

Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy

J. Pinski, E. Klein, D. Penson, 2019, Cancer.

Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.

J. Crowley, R. Herbst, K. Kelly, 2005, Clinical lung cancer.

Results from a phase Ib/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC).

C. Evans, P. Lara, A. Gao, 2019, Journal of Clinical Oncology.

Defining the Optimal Management Strategy for Small Renal Masses

Marc Dall’Era, Primo N. Lara, M. Dall’Era, 2021, Kidney cancer.

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

M. Michaelson, M. Milowsky, William Y. Kim, 2021 .

Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results in encouraging survival in advanced non-small cell lung cancer (NSCLC): Results of a phase II Southwest Oncology Group (SWOG) trial (S0339).

D. Gandara, J. Crowley, P. Gumerlock, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.

P. Paik, E. Felip, J. Grilley-Olson, 2014 .

Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451).

A. Hussain, U. Vaishampayan, T. Flaig, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Trouble with Doublets: Making Sense of Combination Strategies in Advanced Kidney Cancer

S. Pal, P. Lara, 2020 .

Second Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenomics.

J. Crowley, D. Gandara, P. Mack, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accrual issues in genitourinary cancer clinical trials.

P. Lara, R. de Vere White, 2006, Urologic oncology.

The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study.

J. Doroshow, D. Gandara, P. Gumerlock, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evolving epidemiologic trends in nonclear cell renal cell cancer: an analysis of the California Cancer Registry.

P. Lara, Monica Brown, C. Pan, 2013, Urology.

Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

D. Gandara, P. Mack, A. Davies, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy.

D. Gandara, K. Danenberg, P. Danenberg, 2010 .

Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.

K. Kelly, D. Gandara, J. Moon, 2016, Clinical lung cancer.

Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited.

D. Gandara, D. Nguyen, P. Lara, 2008, Archives of internal medicine.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

David C. Smith, E. Small, S. Srinivas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

D. Gandara, E. Heath, W. Stadler, 2010, Urology.

Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).

D. Gandara, P. Mack, S. Gadgeel, 2015 .

Current applications for prostate-specific antigen doubling time.

R. deVere White, P. Lara, C. Evans, 2008, European urology.

The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.

J. Pinski, D. Gandara, D. Quinn, 2007, Clinical genitourinary cancer.

D. Gandara, J. Moon, P. Mack, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).

M. Socinski, K. Kelly, D. Gandara, 2014 .

Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).

H. Kluger, D. Ramies, B. Hellerstedt, 2012 .

Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.

D. Gandara, R. Perez-soler, P. Mack, 2010, Current drug targets.

397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)

K. Nackaerts, B. Hellerstedt, S. Gadgeel, 2010 .